Luteolin exerts anti‐tumour immunity in hepatocellular carcinoma by accelerating CD8 + T lymphocyte infiltration
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Shijiao Cai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Luteolin, CD8-Positive T-Lymphocytes, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Tianjin Medical University General Hospital "Excellent Rising Star" Cultivation Project.
Abstract (Originalsprache)
Luteolin, a commonly used traditional Chinese medicine, has been utilized for several decades in the treatment of hepatocellular carcinoma (HCC). Previous research has demonstrated its anti‐tumour efficacy, but its underlying mechanism remains unclear. This study aimed to assess the therapeutic effects of luteolin in H22 tumour‐bearing mice. luteolin effectively inhibited the growth of solid tumours in a well‐established mouse model of HCC. High‐throughput sequencing revealed that luteolin treatment could enhance T‐cell activation, cell chemotaxis and cytokine production. In addition, luteolin helped sustain a high ratio of CD8 + T lymphocytes in the spleen, peripheral blood and tumour tissues. The effects of luteolin on the phenotypic and functional changes in tumour‐infiltrating CD8 + T lymphocytes were also investigated. Luteolin restored the cytotoxicity of tumour‐infiltrating CD8 + T lymphocytes in H22 tumour‐bearing mice. The CD8 + T lymphocytes exhibited intensified phenotype activation and increased production of granzyme B, IFN‐γ and TNF‐α in serum. The combined administration of luteolin and the PD‐1 inhibitor enhanced the anti‐tumour effects in H22 tumour‐bearing mice. Luteolin could exert an anti‐tumour immune response by inducing CD8 + T lymphocyte infiltration and enhance the anti‐tumour effects of the PD‐1 inhibitor on H22 tumour‐bearing mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Tianjin Medical University General Hospital, Tianjin, China.
- Tianjin Key Laboratory of Digestive Diseases, Department of Gastroenterology and Hepatology, Tianjin Institute of Digestive Diseases, Tianjin Medical University General Hospital, Tianjin, China.
ORCID-Profile: Shijiao Cai, Weilong Zhong
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Tianjin Medical University General Hospital "Excellent Rising Star" Cultivation Project
- "Unveiling and Hanging" Major Projects of Tianjin Science and Technology Bureau
Zitieren
APA
Cai, S., Gou, Y., Chen, Y., Hou, X., Zhang, J., Bi, C., Gu, P., Yang, M., Zhang, H., Zhong, W., & Yuan, H. (2024). Luteolin exerts anti‐tumour immunity in hepatocellular carcinoma by accelerating CD8 + T lymphocyte infiltration. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18535
Vancouver
Cai S, Gou Y, Chen Y, Hou X, Zhang J, Bi C, et al. Luteolin exerts anti‐tumour immunity in hepatocellular carcinoma by accelerating CD8 + T lymphocyte infiltration. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18535
BibTeX
@article{Cai2024,
author = {Cai, Shijiao and Gou, Yidan and Chen, Yanyan and Hou, Xiaoran and Zhang, Jing and Bi, Chongwen and Gu, Peng and Yang, Miao and Zhang, Hanxu and Zhong, Weilong and Yuan, Hengjie},
title = {Luteolin exerts anti‐tumour immunity in hepatocellular carcinoma by accelerating CD8 + T lymphocyte infiltration},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18535}
}
EUVIMED